Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4922261

CCc1n[nH]c2ncnc(N3CCN(c4cccc(Cl)c4)C(C(=O)NCCN4CCOCC4)C3)c12.O=C(O)C(F)(F)F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TP53 P04637 2/20 0.40
USP2 O75604 1/20 0.40
MDM2 Q00987 1/20 0.38
POLB P06746 1/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
PKM P14618 1/20 0.38
SMO Q99835 1/20 0.37
MAPT P10636 2/20 0.37
HTR7 P34969 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1791297 0.95 TP53 (0.43) ALDH1A1KDM4EHPGDSMN1; SMN2TP53
Trifluoroacetic Acid SCHEMBL4933468 0.89 RPS6KB1 (0.37) SMN1; SMN2TP53USP2POLBLMNA
Trifluoroacetic Acid SCHEMBL4930578 0.88 LIMK2 (0.39) SMN1; SMN2TP53LMNAMAPT
Trifluoroacetic Acid SCHEMBL4922821 0.85 MAPT (0.40) SMN1; SMN2TP53LMNAMAPTHTR7
Trifluoroacetic Acid SCHEMBL4933055 0.85 STK4 (0.40) ALDH1A1SMN1; SMN2TP53LMNAMAPT
SCHEMBL1788944 0.83 RPS6KB1 (0.39) SMN1; SMN2TP53USP2POLBLMNA
SCHEMBL2297121 0.82 LIMK2 (0.42) SMN1; SMN2TP53LMNAMAPTHTR7
SCHEMBL1790564 0.82 LIMK2 (0.43) SMN1; SMN2TP53LMNAMAPTHTR7
Trifluoroacetic Acid SCHEMBL4928917 0.82 LIMK2 (0.38) SMN1; SMN2TP53LMNAMAPT
SCHEMBL2296349 0.79 MAPT (0.44) SMN1; SMN2TP53LMNAMAPTHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076338-B2 Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation EXELIXIS, INC. (US) 2011-12-13 US disclosed
US-20080076774-A1 Kinase Modulators and Methods of Use EXELIXIS, INC. (US) 2008-03-27 US disclosed
EP-1750727-A2 KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 EP disclosed
WO-2005117909-A2 KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076774-A1 Kinase Modulators and Methods of Use AKT3, RPS6KA3, CDK3 ALDH1A1 4305/4885KDM4E 1558/4885HPGD 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.